Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06305754 · ClinicalTrials.gov registry record · Phase 3
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
A Phase 3 study of Non-small Cell Lung Cancer (NSCLC), sponsored by Merck Sharp & Dohme.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 520
- Enrollment target
- 20
- Study locations
NCT06305754 is a Phase 3 study of Non-small Cell Lung Cancer (NSCLC) that is actively recruiting participants, run by Merck Sharp & Dohme. The registered enrollment target is 520 participants, above the 280-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (86% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT06305754, a Phase 3 study of Non-small Cell Lung Cancer (NSCLC), is actively recruiting participants, sponsored by Merck Sharp & Dohme.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 520 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate sacituzumab tirumotecan versus pemetrexed in combination with carboplatin for the treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-squamous non-small cell lung cancer (NSCLC). Participants in this study have NSCLC that has continued to progress on prior treatment with EGFR tyrosine kinase inhibitors (TKIs). The primary hypotheses of this study are that sacituzumab tirumotecan is better than platinum-based doublet chemotherapy (pemetrexed and carboplatin) in regard to progression-free survival (PFS) and overall survival (OS).
Conditions Studied
Interventions
- BIOLOGICAL Sacituzumab tirumotecan
- DRUG Carboplatin
- DRUG Pemetrexed
- DRUG H1 Receptor Antagonist
- DRUG H2 Receptor Antagonist
Study Locations (20)
California
- Kaiser Permanente - Oakland ( Site 0054) - Oakland
- Kaiser Permanente - Roseville ( Site 0055) - Roseville
- Kaiser Permanente - San Francisco ( Site 0056) - San Francisco
- Kaiser Permanente - Santa Clara ( Site 0057) - Santa Clara
- Kaiser Permanente-Kaiser Permanente ( Site 0036) - Vallejo
- Kaiser Permanente - Walnut Creek ( Site 0058) - Walnut Creek
Texas
- John Peter Smith Hospital ( Site 0065) - Fort Worth
- University of Texas MD Anderson ( Site 0063) - Houston
- Millennium Research & Clinical Development ( Site 0035) - Houston
Buenos Aires
- Clinica Adventista Belgrano-Oncology ( Site 0315) - Caba.
- Instituto Alexander Fleming ( Site 0307) - Ciudad Autónoma de Buenos Aires
Florida
- Mid Florida Hematology and Oncology Center ( Site 0005) - Orange City
Georgia
- Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital-Research ( Site 0003) - Marietta
Michigan
- University of Michigan ( Site 0009) - Ann Arbor
Missouri
- Cox Medical Center North - Cox Medical Center/ Hematology/Medical Oncology ( Site 0051) - Springfield
New Jersey
- Astera Cancer Care ( Site 0032) - East Brunswick
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 520 participants |
| Start Date | 2024-06-11 |
| Est. Completion | 2030-06-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06305754
The ClinicalTrials.gov registry entry for NCT06305754 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 520 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 280-participant average among 58 other Non-small Cell Lung Cancer (NSCLC) trials with a reported enrollment target (86% higher). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-small Cell Lung Cancer (NSCLC) appearing as the primary indexed condition, and to 5 interventions - of which Sacituzumab tirumotecan is the first listed.
NCT06305754 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Texas, Buenos Aires.
Frequently Asked Questions
What is clinical trial NCT06305754 about?
NCT06305754 is a clinical study titled "Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)". The purpose of this study is to evaluate sacituzumab tirumotecan versus pemetrexed in combination with carboplatin for the treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-squamous non-small cell lung cancer (NSCLC). Participants in this study have NSCLC that has continued t...
What is the current status of trial NCT06305754?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 520 participants. The study started on 2024-06-11. Estimated completion is 2030-06-14.
What conditions does trial NCT06305754 study?
This clinical trial studies the following conditions: Non-small Cell Lung Cancer (NSCLC).
What interventions are being tested in trial NCT06305754?
The interventions under investigation include: Sacituzumab tirumotecan (BIOLOGICAL), Carboplatin (DRUG), Pemetrexed (DRUG), H1 Receptor Antagonist (DRUG), H2 Receptor Antagonist (DRUG).
Who is sponsoring clinical trial NCT06305754?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06305754 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-small Cell Lung Cancer (NSCLC)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
RECRUITING · Phase 3
-
Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)
RECRUITING · Phase 3
-
Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
RECRUITING · Phase 3
-
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
RECRUITING · Phase 3
-
Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.